O TOCILIZUMABE NA TERAPÊUTICA DA COVID-19: UMA REVISÃO DE LITERATURA
O TOCILIZUMABE NA TERAPÊUTICA DA COVID-19: UMA REVISÃO DE LITERATURA
-
DOI: https://doi.org/10.22533/at.ed.4442507105
-
Palavras-chave: Tocilizumabe; covid; tratamento.
-
Keywords: Tocilizumabe; covid; treatment.
-
Abstract: Tocilizumab is a medication studied to treat severe COVID-19, caused by the SARS-CoV-2 virus, ranging from asymptomatic forms to severe cases requiring hospitalization. The search for articles resulted in 1,983 papers analyzed, with 49 articles selected after inclusion criteria, excluding duplicate and unrelated studies. The host's response to the virus, including inflammatory markers like interleukin-6 (IL-6), is associated with disease severity. Tocilizumab blocks the IL-6 receptor, reducing the inflammatory response and potentially improving clinical outcomes. Studies have shown that tocilizumab can reduce the need for mechanical ventilation and improve survival, especially when administered early. Additionally, combining tocilizumab with other treatments, such as PD-1 blockers, has also shown benefits. However, results are varied, and more studies are needed to confirm its efficacy and safety. In summary, tocilizumab is a promising therapeutic option for patients with severe COVID-19, but its use requires caution and further research.
- Lucas Souto Gonçalves Corrêa
- Ramon Fraga de Souza Lima
- Larissa Lima Torres
- Marcel Amaral Fatigati
